BIO-Europe

Qlucore has received approval for a third payment of approximately EUR 0.5 million under its previously awarded EU grant. The total grant amounts to EUR 2.5 million and is distributed across four installments.

The Directed Share Issue was oversubscribed and included both new and existing investors, including Cicero Fonder, Storebrand Sverige Plus and Storebrand Sverige Småbolag Plus as well as Hallberg Management AB, Carl Bennet AB, LINC AB, and Nordea Småbolagsfond Norden.

Cantargia has reported that the first patient has been dosed in a Phase 2 clinical trial investigating nadunolimab in up to 59 current or previous smokers with multifocal high-risk lung nodules, and therefore at risk of developing lung cancer.

Global Health EDCTP3 and the Novo Nordisk Foundation have announced a funding partnership to support research aimed at improving health outcomes in Africa and strengthening global health innovation, with the Novo Nordisk Foundation contributing up to EUR 18 million to the initiative.

Alvotech has announced the pricing of its previously announced underwritten public offering of 22,666,667 of its ordinary shares at an offering price of USD 3.75 per share.

Abera Bioscience has announces that CEPI (Coalition for Epidemic Preparedness Innovations) has decided to extend the ongoing project supporting the development of Abera’s BERA vaccine platform and the company’s innovative influenza vaccine candidate. 

Aplagon has announced the close of a EUR 4.8 million (approx. USD 5.6 million) financing round to support its expansion into a new Phase 2 clinical programme in arteriovenous fistula (AVF) maturation failure in end stage kidney disease.